Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Convertible Debt (2016 - 2021)

Historic Convertible Debt for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Q1 2021 value amounting to $35.5 million.

  • Rocket Pharmaceuticals' Convertible Debt fell 2238.28% to $35.5 million in Q1 2021 from the same period last year, while for Mar 2021 it was $35.5 million, marking a year-over-year decrease of 2238.28%. This contributed to the annual value of $35.1 million for FY2020, which is 2216.03% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Convertible Debt of $35.5 million as of Q1 2021, which was down 2238.28% from $35.1 million recorded in Q4 2020.
  • Over the past 5 years, Rocket Pharmaceuticals' Convertible Debt peaked at $49.4 million during Q3 2017, and registered a low of $35.1 million during Q4 2020.
  • Moreover, its 5-year median value for Convertible Debt was $42.7 million (2019), whereas its average is $43.0 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first soared by 869.06% in 2019, then tumbled by 2238.28% in 2021.
  • Rocket Pharmaceuticals' Convertible Debt (Quarter) stood at $49.4 million in 2017, then fell by 16.08% to $41.4 million in 2018, then increased by 8.69% to $45.0 million in 2019, then dropped by 22.16% to $35.1 million in 2020, then grew by 1.36% to $35.5 million in 2021.
  • Its last three reported values are $35.5 million in Q1 2021, $35.1 million for Q4 2020, and $42.1 million during Q3 2020.